Parkinson patient fibroblasts show increased alpha-synuclein expression

[1]  A. Reichert,et al.  Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.

[2]  S. Poths,et al.  Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein , 2007, Neurogenetics.

[3]  R. Nussbaum,et al.  Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6 , 2007, Neurobiology of Disease.

[4]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[5]  Mauro Fasano,et al.  alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity. , 2006, Biochemical and biophysical research communications.

[6]  R. Nussbaum,et al.  Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.

[7]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[8]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[9]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[10]  T. C. Dickson,et al.  Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection , 2006, Experimental Neurology.

[11]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[12]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Lee,et al.  The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy , 2006, Journal of Neural Transmission.

[14]  W. Langston,et al.  α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates , 2005, Neurobiology of Disease.

[15]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[16]  R. Taichman,et al.  Clusterin inhibits apoptosis by interacting with activated Bax , 2005, Nature Cell Biology.

[17]  A. Ariza,et al.  Differential expression of α‐synuclein isoforms in dementia with Lewy bodies , 2004 .

[18]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[19]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[20]  W. Kunz,et al.  Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients , 2004, Journal of the Neurological Sciences.

[21]  A. Sidhu,et al.  Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .

[22]  D. Allsop,et al.  Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay , 2003, Journal of neurochemistry.

[23]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[24]  L. Petrucelli,et al.  SEPT5_v2 is a parkin-binding protein. , 2003, Brain research. Molecular brain research.

[25]  H. Shibasaki,et al.  Association of the Cytoskeletal GTP-binding Protein Sept4/H5 with Cytoplasmic Inclusions Found in Parkinson's Disease and Other Synucleinopathies* , 2003, Journal of Biological Chemistry.

[26]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[27]  T. Iwaki,et al.  Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with α-synucleinopathies , 2002, Acta Neuropathologica.

[28]  Y. Suh,et al.  α‐Synuclein regulates neuronal survival via Bcl‐2 family expression and PI3/Akt kinase pathway , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[30]  Hsueh‐Meei Huang,et al.  Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease. , 2002, Frontiers in bioscience : a journal and virtual library.

[31]  E. Masliah,et al.  α-Synuclein Protects against Oxidative Stress via Inactivation of the c-Jun N-terminal Kinase Stress-signaling Pathway in Neuronal Cells* , 2002, The Journal of Biological Chemistry.

[32]  J. Trojanowski,et al.  Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease , 2001, Brain Research.

[33]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[34]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[35]  R. Burke,et al.  Increased Expression of Rat Synuclein in the Substantia Nigra Pars Compacta Identified by mRNA Differential Display in a Model of Developmental Target Injury , 1999, Journal of neurochemistry.

[36]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[37]  Y. Mizuno,et al.  bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.

[38]  D. Holtzman.  In vivo effects of apoE and clusterin on amyloid-β metabolism and neuropathology , 2007, Journal of Molecular Neuroscience.

[39]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[40]  D. D. Di Monte,et al.  Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. , 2005, Neurobiology of disease.

[41]  J. Mate,et al.  Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. , 2004, Neuropathology and applied neurobiology.

[42]  Philippe Vernier,et al.  Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  D. Holtzman.  In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. , 2004, Journal of molecular neuroscience : MN.

[44]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[45]  W. Oertel,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. , 2000, Movement disorders : official journal of the Movement Disorder Society.

[46]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.